Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lyra Therapeutics Inc LYRA

Healthcare
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that... see more

Recent & Breaking News (NDAQ:LYRA)

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 21, 2024

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 1, 2024

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 7, 2023

Lyra Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 7, 2023

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

GlobeNewswire October 16, 2023

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

GlobeNewswire September 12, 2023

Lyra Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire September 6, 2023

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

GlobeNewswire August 29, 2023

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 8, 2023

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

GlobeNewswire July 13, 2023

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 2, 2023

Lyra Therapeutics to Present at Jefferies Healthcare Conference

GlobeNewswire June 2, 2023

Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

GlobeNewswire June 1, 2023

Lyra Therapeutics Announces $50.0 Million Private Placement

GlobeNewswire May 26, 2023

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire May 12, 2023

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

GlobeNewswire May 9, 2023

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

GlobeNewswire April 25, 2023

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

GlobeNewswire March 29, 2023

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

GlobeNewswire February 27, 2023

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

GlobeNewswire February 6, 2023